Healthcare - Biotechnology - NASDAQ - US
$ 0.569
2.89 %
$ 65.7 M
Market Cap
-0.65
P/E
CASH FLOW STATEMENT
-124 M
OPERATING CASH FLOW
38 M
INVESTING CASH FLOW
70.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
AlloVir, Inc.
| Net Income | -190 M |
| Depreciation & Amortization | 398 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 40.8 M |
| Change in Working Capital | 2.02 M |
| Others | 27.3 M |
| Free Cash Flow | -124 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (190.4) | (168.7) | (172.0) | (69.8) | (23.8) | (2.4) |
| Depreciation & Amortization | 0.4 | 0.7 | 0.2 | 73 K | 19 K | 3.0 |
| Deferred Income Tax | 0 | 0 | 1.2 | 0 | 0 | 0 |
| Stock Based Compensation | 40.8 | 41.3 | 44.0 | 9.4 | 2.9 | 1.0 |
| Other Operating Activities | 22.8 | 0.8 | 0.9 | 0.5 | (0.6) | (3.0) |
| Change in Working Capital | 2.0 | (16.1) | 19.4 | (1.0) | 1.4 | 3.4 |
| Cash From Operations | (124.5) | (142.1) | (106.3) | (60.8) | (20.2) | 1.9 |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | 0.1 | 26 K | (0.2) | (0.3) | 0 |
| Other Items | 38.0 | (80.6) | 186.0 | (169.3) | (64.3) | 0 |
| Cash From Investing Activities | 38.0 | (80.5) | 186.0 | (169.5) | (64.6) | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | (10.0) |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | 0.5 | 0.2 | (3.5) | 120.9 | 22.9 |
| Cash From Financing Activities | 70.5 | 127.0 | 0.2 | 292.0 | 120.9 | 22.9 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (16.0) | (95.6) | 79.9 | 61.6 | 36.1 | 24.8 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (124.5) | (141.9) | (106.3) | (61.0) | (20.5) | 1.9 |